- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT00977574
Paklitaxel, karboplatina a bevacizumab nebo paklitaxel, karboplatina a temsirolimus nebo ixabepilon, karboplatina a bevacizumab v léčbě pacientek se stadiem III, stadiem IV nebo recidivujícím karcinomem endometria
Randomizovaná tříramenná studie fáze II paklitaxel/karboplatina/bevacizumab (NSC č. 704865), paklitaxel/karboplatina/temsirolimus (NSC č. 683864) a ixabepilon (NSC č. 710428)/karboplatina III pro počáteční léčbu Mevacizumab nebo Bevacizumab Stádium IVB nebo recidivující rakovina endometria
This randomized phase II trial studies paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab to see how well they work in treating patients with stage III, stage IV, or recurrent endometrial cancer. Drugs used in chemotherapy, such as paclitaxel, carboplatin, and ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known which treatment regimen is most effective in treating patients with endometrial cancer.
Přehled studie
Postavení
Podmínky
- Endometriální průhledný adenokarcinom
- Endometriální serózní adenokarcinom
- Endometriální adenokarcinom
- Adenoskvamózní karcinom endometria
- Opakující se zhoubný novorozenec děložního korpusu
- Stage IIIA děložní korpus karcinom nebo karcinosarkom podle fáze AJCC V7
- Stage IIIB děložní karcinom nebo karcinosarkom podle fáze AJCC V7
- Stage IIIC děložní karcinom nebo karcinosarkom podle fáze AJCC V7
- Stage IVA děložní korpus karcinom nebo karcinosarkom podle fáze AJCC V7
- Stage IVB děložní korpus karcinom nebo karcinosarkom podle fáze AJCC V7
Detailní popis
PRIMARY OBJECTIVES:
I. To estimate the hazard of progression or death of each of the three arms relative to that of historical controls in patients with advanced or recurrent endometrial cancer.
SECONDARY OBJECTIVES:
I. To determine the nature, frequency, and maximum degree of toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version (v)3.0 for each of the three arms.
II. To estimate the distribution of the duration of overall survival for each of the three arms.
III. To estimate the proportion of patients with measurable disease who have confirmed objective tumor responses by treatment.
TERTIARY OBJECTIVES:
I. Explore the associations between select biomarkers and progression-free survival as well as secondary measures of clinical outcome (overall survival, tumor response, or disease status if possible) in the context of histologic cell type and treatment.
IA. Somatic mutations in phosphatase and tensin homolog (PTEN)/ phosphoinositide-3-kinase (PI3K) and RAS pathway members by Sequenom mutational profiling and targeted sequencing of candidate genes.
IB. Microsatellite instability by analysis of five National Cancer Institute consensus microsatellite markers (BAT25, BAT26, D2S2123, D5S346, and D17S250) using the Applied Biosystems (ABI) Prism 3100 Genetic Analyzer.
IC. Copy number alterations (gains or losses) by array comparative genomic hybridization (aCGH).
ID. Tumor expression of PTEN and class III beta-tubulin using immunohistochemistry.
IE. Concentration of vascular endothelial growth factor (VEGF) in pre-cycle 1 plasma using an enzyme-linked immunosorbent assay.
II. Explore the relationship among the various biomarkers by histologic subtype and treatment.
III. Explore which combination of biomarkers and clinical covariates optimally predicts responsiveness and resistance to the three treatment arms.
OUTLINE: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients receive paclitaxel intravenously (IV) over 3 hours, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
ARM II: Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus* IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive temsirolimus IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive temsirolimus beginning on course 2.
ARM III: Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab* IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
MAINTENANCE THERAPY: Patients receive bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
NOTE: *Patients undergoing treatment post-surgery (=< 12 weeks) receive bevacizumab beginning on course 2.
After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Typ studie
Zápis (Aktuální)
Fáze
- Fáze 2
Kontakty a umístění
Studijní místa
-
-
Arizona
-
Phoenix, Arizona, Spojené státy, 85013
- Saint Joseph's Hospital and Medical Center
-
Scottsdale, Arizona, Spojené státy, 85259
- Mayo Clinic in Arizona
-
Tucson, Arizona, Spojené státy, 85719
- University of Arizona Cancer Center-North Campus
-
-
California
-
Burbank, California, Spojené státy, 91505
- Providence Saint Joseph Medical Center/Disney Family Cancer Center
-
Concord, California, Spojené státy, 94520
- John Muir Medical Center-Concord
-
La Jolla, California, Spojené státy, 92093
- UC San Diego Moores Cancer Center
-
Los Angeles, California, Spojené státy, 90095
- UCLA / Jonsson Comprehensive Cancer Center
-
Mountain View, California, Spojené státy, 94040
- Palo Alto Medical Foundation-Gynecologic Oncology
-
San Diego, California, Spojené státy, 92103
- UC San Diego Medical Center - Hillcrest
-
San Diego, California, Spojené státy, 92161
- San Diego VA Medical Center
-
San Francisco, California, Spojené státy, 94115
- UCSF Medical Center-Mount Zion
-
Walnut Creek, California, Spojené státy, 94598
- John Muir Medical Center-Walnut Creek
-
-
Colorado
-
Aurora, Colorado, Spojené státy, 80045
- UCHealth University of Colorado Hospital
-
Englewood, Colorado, Spojené státy, 80110
- Rocky Mountain Gynecologic Oncology PC
-
-
Connecticut
-
Hartford, Connecticut, Spojené státy, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
Hartford, Connecticut, Spojené státy, 06102
- Hartford Hospital
-
New Britain, Connecticut, Spojené státy, 06050
- The Hospital of Central Connecticut
-
New Haven, Connecticut, Spojené státy, 06520
- Yale University
-
-
Delaware
-
Lewes, Delaware, Spojené státy, 19958
- Beebe Medical Center
-
Newark, Delaware, Spojené státy, 19718
- Christiana Care Health System-Christiana Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Spojené státy, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Clearwater, Florida, Spojené státy, 33756
- Morton Plant Hospital
-
Jacksonville, Florida, Spojené státy, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Spojené státy, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Orlando, Florida, Spojené státy, 32806
- Orlando Health Cancer Institute
-
Orlando, Florida, Spojené státy, 32803
- AdventHealth Orlando
-
-
Georgia
-
Macon, Georgia, Spojené státy, 31201
- Central Georgia Gynecologic Oncology
-
Savannah, Georgia, Spojené státy, 31404
- Memorial Health University Medical Center
-
-
Hawaii
-
Honolulu, Hawaii, Spojené státy, 96813
- Queen's Medical Center
-
Honolulu, Hawaii, Spojené státy, 96817
- The Cancer Center of Hawaii-Liliha
-
Honolulu, Hawaii, Spojené státy, 96813
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Honolulu, Hawaii, Spojené státy, 96813
- Straub Clinic and Hospital
-
Honolulu, Hawaii, Spojené státy, 96813
- University of Hawaii Cancer Center
-
Honolulu, Hawaii, Spojené státy, 96817
- Queen's Cancer Center - Kuakini
-
Honolulu, Hawaii, Spojené státy, 96826
- Kapiolani Medical Center for Women and Children
-
Lihue, Hawaii, Spojené státy, 96766
- Wilcox Memorial Hospital and Kauai Medical Clinic
-
Wailuku, Hawaii, Spojené státy, 96793
- Maui Memorial Medical Center
-
Wailuku, Hawaii, Spojené státy, 96793
- Pacific Cancer Institute of Maui
-
‘Aiea, Hawaii, Spojené státy, 96701
- Pali Momi Medical Center
-
-
Idaho
-
Boise, Idaho, Spojené státy, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University
-
Chicago, Illinois, Spojené státy, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Spojené státy, 60612
- Rush MD Anderson Cancer Center
-
Elgin, Illinois, Spojené státy, 60123
- Advocate Sherman Hospital
-
Hinsdale, Illinois, Spojené státy, 60521
- Hinsdale Hematology Oncology Associates Incorporated
-
Hinsdale, Illinois, Spojené státy, 60521
- Sudarshan K Sharma MD Limited-Gynecologic Oncology
-
-
Indiana
-
Elkhart, Indiana, Spojené státy, 46515
- Elkhart General Hospital
-
Elkhart, Indiana, Spojené státy, 46514
- Michiana Hematology Oncology PC-Elkhart
-
Elkhart, Indiana, Spojené státy, 46514-2098
- Elkhart Clinic
-
Indianapolis, Indiana, Spojené státy, 46260
- Ascension Saint Vincent Indianapolis Hospital
-
Kokomo, Indiana, Spojené státy, 46904
- Community Howard Regional Health
-
La Porte, Indiana, Spojené státy, 46350
- IU Health La Porte Hospital
-
Mishawaka, Indiana, Spojené státy, 46545
- Michiana Hematology Oncology PC-Mishawaka
-
Mishawaka, Indiana, Spojené státy, 46545
- Saint Joseph Regional Medical Center-Mishawaka
-
Plymouth, Indiana, Spojené státy, 46563
- Michiana Hematology Oncology PC-Plymouth
-
South Bend, Indiana, Spojené státy, 46601
- Memorial Hospital of South Bend
-
South Bend, Indiana, Spojené státy, 46628
- Northern Indiana Cancer Research Consortium
-
South Bend, Indiana, Spojené státy, 46617
- South Bend Clinic
-
Westville, Indiana, Spojené státy, 46391
- Michiana Hematology Oncology PC-Westville
-
-
Iowa
-
Ames, Iowa, Spojené státy, 50010
- McFarland Clinic - Ames
-
Clive, Iowa, Spojené státy, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Spojené státy, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Spojené státy, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Spojené státy, 50316
- Iowa Lutheran Hospital
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa-Wide Oncology Research Coalition NCORP
-
Des Moines, Iowa, Spojené státy, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Spojené státy, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Iowa City, Iowa, Spojené státy, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
West Des Moines, Iowa, Spojené státy, 50266-7700
- Methodist West Hospital
-
West Des Moines, Iowa, Spojené státy, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Chanute, Kansas, Spojené státy, 66720
- Cancer Center of Kansas - Chanute
-
Dodge City, Kansas, Spojené státy, 67801
- Cancer Center of Kansas - Dodge City
-
El Dorado, Kansas, Spojené státy, 67042
- Cancer Center of Kansas - El Dorado
-
Fort Scott, Kansas, Spojené státy, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Spojené státy, 67301
- Cancer Center of Kansas-Independence
-
Kansas City, Kansas, Spojené státy, 66160
- University of Kansas Cancer Center
-
Kingman, Kansas, Spojené státy, 67068
- Cancer Center of Kansas-Kingman
-
Lawrence, Kansas, Spojené státy, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Spojené státy, 67905
- Cancer Center of Kansas-Liberal
-
McPherson, Kansas, Spojené státy, 67460
- Cancer Center of Kansas - McPherson
-
Newton, Kansas, Spojené státy, 67114
- Cancer Center of Kansas - Newton
-
Parsons, Kansas, Spojené státy, 67357
- Cancer Center of Kansas - Parsons
-
Pratt, Kansas, Spojené státy, 67124
- Cancer Center of Kansas - Pratt
-
Salina, Kansas, Spojené státy, 67401
- Cancer Center of Kansas - Salina
-
Wellington, Kansas, Spojené státy, 67152
- Cancer Center of Kansas - Wellington
-
Wichita, Kansas, Spojené státy, 67214
- Ascension Via Christi Hospitals Wichita
-
Wichita, Kansas, Spojené státy, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, Spojené státy, 67214
- Cancer Center of Kansas - Wichita
-
Wichita, Kansas, Spojené státy, 67208
- Associates In Womens Health
-
Wichita, Kansas, Spojené státy, 67214
- Wichita NCI Community Oncology Research Program
-
Winfield, Kansas, Spojené státy, 67156
- Cancer Center of Kansas - Winfield
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Spojené státy, 40503
- Baptist Health Lexington
-
Louisville, Kentucky, Spojené státy, 40202
- The James Graham Brown Cancer Center at University of Louisville
-
-
Maine
-
Portland, Maine, Spojené státy, 04102
- MaineHealth Maine Medical Center - Portland
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21237
- MedStar Franklin Square Medical Center/Weinberg Cancer Institute
-
Baltimore, Maryland, Spojené státy, 21215
- Sinai Hospital of Baltimore
-
Baltimore, Maryland, Spojené státy, 21204
- Greater Baltimore Medical Center
-
Elkton, Maryland, Spojené státy, 21921
- Christiana Care - Union Hospital
-
-
Massachusetts
-
Springfield, Massachusetts, Spojené státy, 01199
- Baystate Medical Center
-
Worcester, Massachusetts, Spojené státy, 01605
- UMass Memorial Medical Center - Memorial Division
-
-
Michigan
-
Ann Arbor, Michigan, Spojené státy, 48106
- Michigan Cancer Research Consortium NCORP
-
Ann Arbor, Michigan, Spojené státy, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Dearborn, Michigan, Spojené státy, 48124
- Corewell Health Dearborn Hospital
-
Detroit, Michigan, Spojené státy, 48236
- Henry Ford Health Saint John Hospital
-
Flint, Michigan, Spojené státy, 48532
- Genesys Regional Medical Center-West Flint Campus
-
Flint, Michigan, Spojené státy, 48503
- Hurley Medical Center
-
Jackson, Michigan, Spojené státy, 49201
- Allegiance Health
-
Kalamazoo, Michigan, Spojené státy, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Spojené státy, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, Spojené státy, 49048
- Beacon Kalamazoo
-
Lansing, Michigan, Spojené státy, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Spojené státy, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Niles, Michigan, Spojené státy, 49120
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Pontiac, Michigan, Spojené státy, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Port Huron, Michigan, Spojené státy, 48060
- Lake Huron Medical Center
-
Royal Oak, Michigan, Spojené státy, 48073
- Corewell Health William Beaumont University Hospital
-
Saginaw, Michigan, Spojené státy, 48601
- MyMichigan Medical Center Saginaw
-
Saint Joseph, Michigan, Spojené státy, 49085
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Spojené státy, 49085
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Warren, Michigan, Spojené státy, 48093
- Henry Ford Health Warren Hospital
-
-
Minnesota
-
Rochester, Minnesota, Spojené státy, 55905
- Mayo Clinic in Rochester
-
-
Mississippi
-
Jackson, Mississippi, Spojené státy, 39216
- University of Mississippi Medical Center
-
Jackson, Mississippi, Spojené státy, 39216
- Saint Dominic-Jackson Memorial Hospital
-
Pascagoula, Mississippi, Spojené státy, 39581
- Singing River Hospital
-
-
Missouri
-
Columbia, Missouri, Spojené státy, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Rolla, Missouri, Spojené státy, 65401
- Phelps Health Delbert Day Cancer Institute
-
Springfield, Missouri, Spojené státy, 65804
- Cancer Research for the Ozarks NCORP
-
Springfield, Missouri, Spojené státy, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, Spojené státy, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Spojené státy, 63104
- SSM Health Saint Louis University Hospital
-
-
Nebraska
-
Omaha, Nebraska, Spojené státy, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, Spojené státy, 89106
- Women's Cancer Center of Nevada
-
Reno, Nevada, Spojené státy, 89502
- Renown Regional Medical Center
-
Reno, Nevada, Spojené státy, 89502
- Center of Hope at Renown Medical Center
-
-
New Jersey
-
Camden, New Jersey, Spojené státy, 08103
- Cooper Hospital University Medical Center
-
Morristown, New Jersey, Spojené státy, 07960
- Morristown Medical Center
-
Mount Holly, New Jersey, Spojené státy, 08060
- Virtua Memorial
-
Newark, New Jersey, Spojené státy, 07101
- Rutgers New Jersey Medical School
-
Phillipsburg, New Jersey, Spojené státy, 08865
- Saint Luke's Hospital-Warren Campus
-
Summit, New Jersey, Spojené státy, 07902
- Overlook Hospital
-
Voorhees Township, New Jersey, Spojené státy, 08043
- Virtua Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, Spojené státy, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, Spojené státy, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Spojené státy, 12208
- Women's Cancer Care Associates LLC
-
Brightwaters, New York, Spojené státy, 11718
- Island Gynecologic Oncology
-
Brooklyn, New York, Spojené státy, 11203
- State University of New York Downstate Medical Center
-
Buffalo, New York, Spojené státy, 14263
- Roswell Park Cancer Institute
-
Fresh Meadows, New York, Spojené státy, 11365
- New York Hospital Medical Center of Queens
-
New York, New York, Spojené státy, 10065
- Memorial Sloan Kettering Cancer Center
-
Stony Brook, New York, Spojené státy, 11794
- Stony Brook University Medical Center
-
-
North Carolina
-
Asheville, North Carolina, Spojené státy, 28816
- Hope Women's Cancer Centers-Asheville
-
Burlington, North Carolina, Spojené státy, 27215
- Cone Health Cancer Center at Alamance Regional
-
Charlotte, North Carolina, Spojené státy, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
Charlotte, North Carolina, Spojené státy, 28204
- Novant Health Presbyterian Medical Center
-
Durham, North Carolina, Spojené státy, 27710
- Duke University Medical Center
-
Winston-Salem, North Carolina, Spojené státy, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Spojené státy, 44307
- Cleveland Clinic Akron General
-
Akron, Ohio, Spojené státy, 44304
- Summa Health System - Akron Campus
-
Cincinnati, Ohio, Spojené státy, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, Spojené státy, 44106
- Case Western Reserve University
-
Cleveland, Ohio, Spojené státy, 44109
- MetroHealth Medical Center
-
Cleveland, Ohio, Spojené státy, 44195
- Cleveland Clinic Foundation
-
Cleveland, Ohio, Spojené státy, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, Spojené státy, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, Spojené státy, 43210
- Ohio State University Comprehensive Cancer Center
-
Dayton, Ohio, Spojené státy, 45409
- Miami Valley Hospital
-
Kettering, Ohio, Spojené státy, 45429
- Kettering Medical Center
-
Mayfield Heights, Ohio, Spojené státy, 44124
- Hillcrest Hospital Cancer Center
-
Mentor, Ohio, Spojené státy, 44060
- UH Seidman Cancer Center at Lake Health Mentor Campus
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Spojené státy, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, Spojené státy, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Pennsylvania
-
Abington, Pennsylvania, Spojené státy, 19001
- Jefferson Abington Hospital
-
Allentown, Pennsylvania, Spojené státy, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Danville, Pennsylvania, Spojené státy, 17822
- Geisinger Medical Center
-
Hazleton, Pennsylvania, Spojené státy, 18201
- Geisinger Medical Center-Cancer Center Hazleton
-
Hershey, Pennsylvania, Spojené státy, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Philadelphia, Pennsylvania, Spojené státy, 19111
- Fox Chase Cancer Center
-
Philadelphia, Pennsylvania, Spojené státy, 19107
- Pennsylvania Hospital
-
State College, Pennsylvania, Spojené státy, 16801
- Geisinger Medical Group
-
West Reading, Pennsylvania, Spojené státy, 19611
- Reading Hospital
-
Wilkes-Barre, Pennsylvania, Spojené státy, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02905
- Women and Infants Hospital
-
-
South Carolina
-
Charleston, South Carolina, Spojené státy, 29425
- Medical University of South Carolina
-
Columbia, South Carolina, Spojené státy, 29210
- South Carolina Oncology Associates PA
-
-
South Dakota
-
Sioux Falls, South Dakota, Spojené státy, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, Spojené státy, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, Spojené státy, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt University/Ingram Cancer Center
-
-
Texas
-
Dallas, Texas, Spojené státy, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Spojené státy, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Spojené státy, 75390
- Clements University Hospital
-
Galveston, Texas, Spojené státy, 77555-0565
- University of Texas Medical Branch
-
Houston, Texas, Spojené státy, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, Spojené státy, 77030
- UT MD Anderson Cancer Center
-
Temple, Texas, Spojené státy, 76508
- Scott and White Memorial Hospital
-
-
Vermont
-
Burlington, Vermont, Spojené státy, 05401
- University of Vermont Medical Center
-
-
Virginia
-
Charlottesville, Virginia, Spojené státy, 22908
- University of Virginia Cancer Center
-
Hampton, Virginia, Spojené státy, 23666
- Virginia Oncology Associates-Hampton
-
Norfolk, Virginia, Spojené státy, 23502
- Virginia Oncology Associates - Norfolk
-
Richmond, Virginia, Spojené státy, 23298
- VCU Massey Comprehensive Cancer Center
-
Roanoke, Virginia, Spojené státy, 24033
- Carilion Roanoke Memorial Hospital
-
-
Washington
-
Bellingham, Washington, Spojené státy, 98226
- PeaceHealth Medical Group PC
-
Everett, Washington, Spojené státy, 98201
- Providence Regional Cancer Partnership
-
Mount Vernon, Washington, Spojené státy, 98274
- Skagit Regional Health Cancer Care Center
-
Poulsbo, Washington, Spojené státy, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, Spojené státy, 98122
- Swedish Medical Center-First Hill
-
Seattle, Washington, Spojené státy, 98195
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Spojené státy, 98112
- Kaiser Permanente Washington
-
Seattle, Washington, Spojené státy, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, Spojené státy, 98109
- Fred Hutchinson Cancer Center
-
Seattle, Washington, Spojené státy, 98133
- University of Washington Medical Center - Northwest
-
Sequim, Washington, Spojené státy, 98384
- Olympic Medical Cancer Care Center
-
Silverdale, Washington, Spojené státy, 98383
- Saint Joseph Medical Center Hematology and Oncology - Silverdale
-
Spokane, Washington, Spojené státy, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, Spojené státy, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Tacoma, Washington, Spojené státy, 98405
- MultiCare Tacoma General Hospital
-
Tacoma, Washington, Spojené státy, 98405
- Saint Joseph Medical Center
-
Walla Walla, Washington, Spojené státy, 99362
- Providence Saint Mary Regional Cancer Center
-
Wenatchee, Washington, Spojené státy, 98801
- Wenatchee Valley Hospital and Clinics
-
-
Wisconsin
-
La Crosse, Wisconsin, Spojené státy, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, Spojené státy, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Spojené státy, 53226
- Medical College of Wisconsin
-
Milwaukee, Wisconsin, Spojené státy, 53215
- Aurora Saint Luke's Medical Center
-
Milwaukee, Wisconsin, Spojené státy, 53233
- Aurora Sinai Medical Center
-
Oshkosh, Wisconsin, Spojené státy, 54904
- Vince Lombardi Cancer Clinic - Oshkosh
-
Sheboygan, Wisconsin, Spojené státy, 53081
- Vince Lombardi Cancer Clinic-Sheboygan
-
West Allis, Wisconsin, Spojené státy, 53227
- Aurora West Allis Medical Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
Patients must have measurable stage III, measurable stage IVA, stage IVB (with or without measurable disease) or recurrent (with or without measurable disease) endometrial carcinoma
- Histologic confirmation of the original primary tumor is required; patients with the following histologic epithelial cell types are eligible: endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, adenocarcinoma not otherwise specified (N.O.S.), mucinous adenocarcinoma, squamous cell carcinoma, and transitional cell carcinoma
-
Measurable disease is defined by Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.1); measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
-
Patients must have Gynecologic Oncology Group (GOG) performance status of 0, 1, or 2
-
Patients must not be eligible for a higher priority GOG protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population
-
Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl equivalent to Common Terminology Criteria (CTCAE v3.0) grade 1
-
Platelets greater than or equal to 100,000/mcl
-
Creatinine less than or equal to 1.5 times institutional upper limit normal (ULN), CTCAE v3.0 grade 1
-
Bilirubin less than or equal to 1.5 x ULN (CTCAE v3.0 grade 1)
-
Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Alkaline phosphatase less than or equal to 2.5 x ULN (CTCAE v3.0 grade 1)
-
Urine protein creatinine (UPC) ratio must be < 1.0 gram (gm); if UPC ratio >= 1, collection of 24-hour urine measurement of urine protein is recommended (24-hour urine protein level must be < 1000 mg for patient enrollment)
-
UPC ratio of spot urine is an estimation of the 24 urine protein excretion
- A UPC ratio of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
-
-
Prothrombin time (PT) such that international normalized ratio (INR) is =< 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin) and a partial thromboplastin time (PTT) =< 1.5 x ULN
-
Fasting cholesterol less than 300 mg/dL (CTCAE v3.0 grade 1)
-
Fasting triglycerides =< 2.5 x ULN (CTCAE v3.0 grade 1)
-
Patients must NOT have received prior chemotherapy or targeted therapy, including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma
-
Patients must NOT have received prior therapy with bevacizumab or other VEGF pathway targeted therapy; patients must NOT have received prior therapy with temsirolimus, everolimus, ridaforolimus, sirolimus, or any other PI3K/ v-akt murine thymoma viral oncogene homolog 1 (AKT)/mammalian target of rapamycins (mTor) pathway targeted therapy
-
Patients may have receive prior radiation therapy for treatment of endometrial carcinoma; prior radiation therapy may have included pelvic radiation therapy, extended field pelvic/para-aortic radiation therapy, and/or intravaginal brachytherapy; all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy; the prior radiation field, radiation dose, number of fractions and prior radiation start and stop dates must be provided on the Fast Fact Sheet (FFS) at registration
-
Patients may have received prior hormonal therapy for treatment of endometrial carcinoma; all hormonal therapy must be discontinued at least one week prior to the first date of study therapy
-
Patients must have signed an approved informed consent and authorization permitting release of personal health information
Exclusion Criteria:
-
Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, and other specific malignancies as noted below, are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
-
Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of endometrial cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
-
Patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last three years are excluded; patients may have received prior adjuvant chemotherapy for localized breast cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
-
Patients with serious, non-healing wound, ulcer, or bone fracture; this includes history of abdominal/pelvic fistula, gastrointestinal perforation or intra-abdominal abscess within 3 months prior to the first date of study therapy; patients with underlying lesions that caused the fistula or perforation in the past that have not been corrected
-
Patients with active bleeding or pathologic conditions that carry high risk of bleeding, such as known bleeding disorder, coagulopathy, or tumor involving major vessels
-
Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, seizures not controlled with standard medical therapy or any brain metastases
-
Patients with clinically significant cardiovascular disease; this includes:
- Uncontrolled hypertension, defined as systolic > 150 mm Hg or diastolic > 90 mm Hg
- Myocardial infarction or unstable angina within 6 months of the first date of study therapy
- New York Heart Association (NYHA) class II or greater congestive heart failure
- History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation) or cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)
- CTCAE grade 2 or greater peripheral vascular disease.
- History of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of study therapy.
- Aortic aneurysm and/or history of aortic dissection
-
Patients with known hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies
-
Patients undergoing invasive procedures as defined below:
- Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to the first date of bevacizumab or temsirolimus therapy
- Major surgical procedure anticipated during the course of the study.
- Minor surgical procedures, fine needle aspirates, or core biopsies within 7 days prior to the first date of study therapy
-
Patients with known prior history of interstitial pneumonitis
-
Patients with CTCAE v. 3, grade 2 or greater hypoxemia
-
Patients with CTCAE v. 3, grade 2 or greater dyspnea
-
Patients must not have uncontrolled diabetes, and must not have baseline hemoglobin A1C (HgbA1C) > 8
-
Patients with peripheral neuropathy > CTCAE v.3, grade 1
-
Patients who are pregnant or nursing
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Arm I (paclitaxel, carboplatin, bevacizumab)
Patients receive paclitaxel IV over 3 hours, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Correlative studies Given IV
Ostatní jména:
|
|
Experimentální: Arm II (paclitaxel, carboplatin, temsirolimus)
Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1 and temsirolimus IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Correlative studies Given IV
Ostatní jména:
|
|
Experimentální: Arm III (ixabepilone, carboplatin, bevacizumab)
Patients receive ixabepilone IV over 1 hour, carboplatin IV over 30 minutes, and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. |
Given IV
Ostatní jména:
Correlative studies Given IV
Ostatní jména:
Given IV
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Number of Participants Who Progressed or Died by 25 Months From Enrollment
Časové okno: at 25 months
|
PFS (Progression free survival) is defined as the duration of time from date of study entry to time of progression or death, whichever occurs first. Patients with a status of alive, progression-free are censored at their date of last follow-up. To lessen the potential for bias in the progression evaluation times between treatment arms and historical controls, progression/death times will be grouped over 6 18-week time intervals. Progressions are carried forward to the end of the interval. All progressions or deaths occurring after the 6th 18-week interval are censored at 25 months for this analysis. Study NCT00977574 |
at 25 months
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Frekvence a závažnost toxicity podle CTCAE v3.0 pro každou ze tří paží.
Časové okno: Medián 10 cyklů léčby plus 30 dnů
|
Medián 10 cyklů léčby plus 30 dnů
|
|
|
The Median Duration of Overall Survival for Each of the Three Arms.
Časové okno: Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. |
Time from date of study entry to time of death or the date of last contact, assessed up to 5 years
|
|
The Proportion of Patients With Measurable Disease Who Have Confirmed Objective Tumor Responses by Treatment.
Časové okno: Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
RECIST 1.1 was used to define objective tumor response. A complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. A partial response is defined as At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. There can be no unequivocal progression of non-target lesions and no new lesions. Complete and partial responses are included in the objective tumor response rate. Confirmation of response was not required. |
Imaging was done every 3 cycles and at any other time clinically indicated. Imaging was required every 9 weeks until progression or initiation on non protocol therapy. After 2 years of protocol therapy or follow up, CT scan or MRI was every 3 months
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Carol Aghajanian, NRG Oncology
Publikace a užitečné odkazy
Obecné publikace
- Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK. TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol. 2022 Oct 1;40(28):3289-3300. doi: 10.1200/JCO.21.02506. Epub 2022 Jun 3.
- Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C. Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study. Gynecol Oncol. 2021 Apr;161(1):113-121. doi: 10.1016/j.ygyno.2021.01.025. Epub 2021 Feb 2.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Aktuální)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhadovaný)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Aminokyseliny, peptidy a proteiny
- Proteiny
- Sloučeniny síry
- Organické chemikálie
- Uhlovodíky
- Cykloparafiny
- Uhlovodíky, alicyklické
- Uhlovodíky, cyklické
- Terpeny
- Protilátky, monoklonální, humanizované
- Protilátky, monoklonální
- Protilátky
- Imunoglobuliny
- Imunoproteiny
- Krevní proteiny
- Sérové globuliny
- Globuliny
- Anorganické chemikálie
- Koordinační komplexy
- Taxoidy
- Cyclodecanes
- Diterpeny
- Ekonomika a organizace zdravotní péče
- Makrolidy
- Laktony
- Izotypy imunoglobulinu
- Sulfidy
- Anionty
- Ionty
- Elektrolyty
- Sirovodík
- Polyketidy
- Ekonomika
- Bevacizumab
- Sirolimus
- Karboplatina
- Paklitaxel
- Imunoglobulin G
- Epothilony
- Disulfidy
- Temsirolimus
- Ixabepilone
- Daně
Další identifikační čísla studie
- NCI-2011-01969
- U10CA180868 (Grant/smlouva NIH USA)
- U10CA027469 (Grant/smlouva NIH USA)
- NCI-2011-01969 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- GOG-0086P (Jiný identifikátor: CTEP)
- CDR0000654472
- GOG-0086P
- GOG-0086P (Jiný identifikátor: NRG Oncology)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .